ReviewBlood2025
FDA-approved therapies for chronic GVHD.
Review in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies.Transplantation and cellular therapy · 2025Trial
- Article
- Designing immune reconstitution to prevent graft-versus-host disease: a novel therapeutic paradigm beyond T cell suppression.International journal of hematology · 2026Review
- Patient-reported outcomes in chronic GVHD: instruments, clinical utility, and survivorship integration.Journal of patient-reported outcomes · 2026Review
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Acute and Chronic Cutaneous Graft-versus-Host Disease: Diagnosis, Treatment, and Emerging Directions.American journal of clinical dermatology · 2026Review
- The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGVHD.Bone marrow transplantation · 2026Article
- Reconsidering an age-old question.Blood advances · 2026Article
- No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.Blood advances · 2026Article
- Chronic Graft-versus-Host disease trends over 30 years - a study by the EBMT transplant complications working party.Bone marrow transplantation · 2025Article
- Cellular Therapy for Systemic Autoimmune Diseases: New Opportunities for Future Research and Interdisciplinary Collaboration.ACR open rheumatology · 2025Review
- Review
- Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
abstactDespite novel prophylactic regimens, chronic graft-versus-host disease (cGVHD) remains a challenging complication after allogeneic hematopoietic cell transplantation. cGVHD can affect multiple organs and reduces quality of life, and treatment can cause serious adverse effects. In the past 10 years, the drugs ibrutinib, ruxolitinib, belumosudil, and axatilimab were approved by the US Food and Drug Administration (FDA) for cGVHD. Here, we discuss which signaling pathways and cell types are targeted, the clinical studies that were the basis for FDA approval, and future directions for clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.